Acoramidis
Wild-type ATTR-CM (ATTRwt-CM)
Eidos Therapeutics, a BridgeBio companySmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Wild-type ATTR-CM (ATTRwt-CM) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
TAURURSODIOL Fondazione IRCCS Policlinico San Matteo di Pavia | Phase 3 | BB |
Doxycycline Fondazione IRCCS Policlinico San Matteo di Pavia | Phase 3 | B |
Ntla-2001 Intellia Therapeutics | Phase 1 | NR |
Patisiran Austin Neuromuscular Center | Early Phase 1 | NR |
Dobutrex Steen Hvitfeldt Poulsen | Phase 1/2 | NR |
nnc6019-0001 Novo Nordisk A/S | Phase 3 | NR |
Same molecule, other indications
Acoramidis is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →